Swedish Orphan Biovitrum Stock Current Valuation
| B6E Stock | EUR 26.44 0.04 0.15% |
Valuation analysis of Swedish Orphan Biovitrum helps investors to measure Swedish Orphan's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Swedish Orphan's price fluctuation is not too volatile at this time. Calculation of the real value of Swedish Orphan Biovitrum is based on 3 months time horizon. Increasing Swedish Orphan's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Swedish stock is determined by what a typical buyer is willing to pay for full or partial control of Swedish Orphan Biovitrum. Since Swedish Orphan is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Swedish Stock. However, Swedish Orphan's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.44 | Real 22.64 | Hype 26.48 | Naive 24.86 |
The real value of Swedish Stock, also known as its intrinsic value, is the underlying worth of Swedish Orphan Biovitrum Company, which is reflected in its stock price. It is based on Swedish Orphan's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Swedish Orphan's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Swedish Orphan Biovitrum helps investors to forecast how Swedish stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Swedish Orphan more accurately as focusing exclusively on Swedish Orphan's fundamentals will not take into account other important factors: Swedish Orphan Biovitrum Company Current Valuation Analysis
Swedish Orphan's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Swedish Orphan Current Valuation | 6.67 B |
Most of Swedish Orphan's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Swedish Orphan Biovitrum has a Current Valuation of 6.67 B. This is 53.53% lower than that of the Healthcare sector and 10.22% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Germany stocks is 59.85% higher than that of the company.
Swedish Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Swedish Orphan's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Swedish Orphan could also be used in its relative valuation, which is a method of valuing Swedish Orphan by comparing valuation metrics of similar companies.Swedish Orphan is rated below average in current valuation category among its peers.
Swedish Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 6.67 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 69.59 % | |||
| Price To Earning | 18.28 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 3.66 X | |||
| Revenue | 15.53 B | |||
| Gross Profit | 14.38 B | |||
| EBITDA | 5.72 B | |||
| Net Income | 2.68 B | |||
| Cash And Equivalents | 280.15 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 8.78 B | |||
| Debt To Equity | 39.80 % | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 0.93 X | |||
| Price To Earnings To Growth | 33.82 X | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.39 | |||
| Market Capitalization | 6.36 B | |||
| Total Asset | 48.66 B | |||
| Net Asset | 48.66 B |
About Swedish Orphan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Swedish Stock
Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.